Clinical trial
Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC.
NCT03995875 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC.
- Lead sponsor
- AstraZeneca
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 25, 2019
- Completion date
- January 11, 2024
- Enrollment
- 529 (actual)
- Sites
- 43
Conditions
As the registry lists them; a condition with its own page is linked.